image credit- freepik
US-based Charles River Laboratories International, and Medigen Vaccine Biologics Corp. (MVC), headquartered in Taiwan, have collaborated on the characterisation and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine.
Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent enterovirus vaccine.
MVC's proprietary ENVACGEN® Enterovirus 71 Vaccine has been approved in Taiwan and Vietnam, demonstrating the company's proven capability to develop and manufacture vaccines that meet international quality standards.
Building on this success, MVC is advancing the development of its next-generation multivalent enterovirus vaccine and selected Charles River as its strategic partner to accelerate the programme by leveraging the company's global expertise in virology, biologics testing, non-clinical development, and regulatory science.
The companies aim to generate robust data to support IND applications and future global clinical development.
